Beta Drugs Statistics

Total Valuation

Beta Drugs has a market cap or net worth of INR 17.11 billion. The enterprise value is 17.02 billion.

Market Cap	17.11B
Enterprise Value	17.02B

Important Dates

The last earnings date was Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	n/a

Share Statistics

Beta Drugs has 10.09 million shares outstanding. The number of shares has decreased by -0.01% in one year.

Current Share Class	n/a
Shares Outstanding	10.09M
Shares Change (YoY)	-0.01%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.25%
Float	n/a

Valuation Ratios

The trailing PE ratio is 41.73.

PE Ratio	41.73
Forward PE	n/a
PS Ratio	5.11
PB Ratio	9.46
P/TBV Ratio	9.75
P/FCF Ratio	127.19
P/OCF Ratio	67.96
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 26.12, with an EV/FCF ratio of 126.53.

EV / Earnings	41.52
EV / Sales	5.09
EV / EBITDA	26.12
EV / EBIT	30.50
EV / FCF	126.53

Financial Position

The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.11.

Current Ratio	2.15
Quick Ratio	1.33
Debt / Equity	0.11
Debt / EBITDA	0.29
Debt / FCF	1.42
Interest Coverage	17.81

Financial Efficiency

Return on equity (ROE) is 25.40% and return on invested capital (ROIC) is 19.52%.

Return on Equity (ROE)	25.40%
Return on Assets (ROA)	13.12%
Return on Invested Capital (ROIC)	19.52%
Return on Capital Employed (ROCE)	28.29%
Revenue Per Employee	9.02M
Profits Per Employee	1.11M
Employee Count	371
Asset Turnover	1.26
Inventory Turnover	4.04

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +31.94% in the last 52 weeks. The beta is -0.07, so Beta Drugs's price volatility has been lower than the market average.

Beta (5Y)	-0.07
52-Week Price Change	+31.94%
50-Day Moving Average	1,748.16
200-Day Moving Average	1,714.77
Relative Strength Index (RSI)	40.55
Average Volume (20 Days)	3,439

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Beta Drugs had revenue of INR 3.35 billion and earned 410.00 million in profits. Earnings per share was 40.62.

Revenue	3.35B
Gross Profit	1.34B
Operating Income	558.12M
Pretax Income	549.48M
Net Income	410.00M
EBITDA	651.66M
EBIT	558.12M
Earnings Per Share (EPS)	40.62

Full Income Statement

Balance Sheet

The company has 278.87 million in cash and 190.60 million in debt, giving a net cash position of 88.28 million or 8.75 per share.

Cash & Cash Equivalents	278.87M
Total Debt	190.60M
Net Cash	88.28M
Net Cash Per Share	8.75
Equity (Book Value)	1.81B
Book Value Per Share	179.18
Working Capital	1.11B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 251.78 million and capital expenditures -117.25 million, giving a free cash flow of 134.53 million.

Operating Cash Flow	251.78M
Capital Expenditures	-117.25M
Free Cash Flow	134.53M
FCF Per Share	13.33

Full Cash Flow Statement

Margins

Gross margin is 39.90%, with operating and profit margins of 16.67% and 12.25%.

Gross Margin	39.90%
Operating Margin	16.67%
Pretax Margin	16.41%
Profit Margin	12.25%
EBITDA Margin	19.47%
EBIT Margin	16.67%
FCF Margin	4.02%

Dividends & Yields

Beta Drugs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.01%
Shareholder Yield	0.01%
Earnings Yield	2.40%
FCF Yield	0.79%

Stock Splits

The last stock split was on March 26, 2025. It was a forward split with a ratio of 1.05.

Last Split Date	Mar 26, 2025
Split Type	Forward
Split Ratio	1.05

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a